mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant.
McGrath, Marisa E
O'Meara, Timothy R
Dillen, Carly A
Xu, Andrew Z
Ernst, Robert K
Barouch, Dan H
Frieman, Matthew B
Dowling, David J
MetadataShow full item record
AbstractThe SARS-CoV-2 Omicron variant evades vaccine-induced immunity. While a booster dose of ancestral mRNA vaccines effectively elicits neutralizing antibodies against variants, its efficacy against Omicron in older adults, who are at the greatest risk of severe disease, is not fully elucidated. Here, we evaluate multiple longitudinal immunization regimens of mRNA BNT162b2 to assess the effects of a booster dose provided >8 months after the primary immunization series across the murine lifespan, including in aged 21-month-old mice. Boosting dramatically enhances humoral and cell-mediated responses with evidence of Omicron cross-recognition. Furthermore, while younger mice are protected without a booster dose, boosting provides sterilizing immunity against Omicron-induced lung infection in aged 21-month-old mice. Correlational analyses reveal that neutralizing activity against Omicron is strongly associated with protection. Overall, our findings indicate age-dependent vaccine efficacy and demonstrate the potential benefit of mRNA booster immunization to protect vulnerable older populations against SARS-CoV-2 variants.
Data AvailibilityThe authors declare that all data supporting the findings of this study are available within the supplementary information files (Supplementary Data 1 https://www.nature.com/articles/s42003-022-03765-3#MOESM4).
Data / Code Locationhttps://www.nature.com/articles/s42003-022-03765-3#MOESM4
Rights/Terms© 2022. The Author(s).
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19537
- Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
- Authors: Gupta SL, Mantus G, Manning KE, Ellis M, Patel M, Ciric CR, Lu A, Turner JS, O'Halloran JA, Presti RM, Joshi DJ, Ellebedy AH, Anderson EJ, Rostad CA, Suthar MS, Wrammert J
- Issue date: 2022 Sep 14
- Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
- Authors: Desmecht S, Tashkeev A, El Moussaoui M, Marechal N, Perée H, Tokunaga Y, Fombellida-Lopez C, Polese B, Legrand C, Wéry M, Mni M, Fouillien N, Toussaint F, Gillet L, Bureau F, Lutteri L, Hayette MP, Moutschen M, Meuris C, Vermeersch P, Desmecht D, Rahmouni S, Darcis G
- Issue date: 2022
- Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
- Authors: Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y
- Issue date: 2022 May 2
- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
- Authors: Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, Smatti MK, Tang P, Hasan MR, Coyle P, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R
- Issue date: 2022 May 12
- Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
- Authors: Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, Wagatsuma A, Numata N, Sasaki K, Kuzuoka T, Yato Y, Takahashi Y, Maeda K, Suzuki T, Mizukami T, Hamaguchi I
- Issue date: 2022 Jun 10